March 20, 2019
Gilead Japan President Luc Hermans Gilead Sciences is confident that its soon-to-be-approved HIV triplet Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide fumarate (TAF)) will be an enormous success in Japan just as it has been in the US and Europe,...read more